Pharming expands KL1333 licensing deal with Yungjin Pharm, gains Japan commercialization rights

Pharming Group and partner Yungjin Pharm signed an amended agreement for mitochondrial disease drug candidate KL1333 (napazimone), under which Pharming acquires commercialization rights for Japan while Yungjin retains South Korean market rights. KL1333 is in a Phase 2 'FALCON' clinical trial for primary mitochondrial disease.

Detected & updated continuously · Source: Nebula